Announcements Trials
Browse Landscape

Status

Active not recruiting 3Completed 2Terminated 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 209Observational 6Expanded_access 1

Sponsor

Cancer Type

Breast 5Tumor-Agnostic 1

Conditions

Breast Neoplasms 4Neoplasms, Second Primary 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1HER2-positive Breast Cancer 1

Interventions

Blood Specimen Collection 131Surveys and Questionnaires 130Specimen Handling 57Observation 55Radiotherapy 44Interviews as Topic 34Surgical Procedures, Operative 32Drug Therapy 31Biopsy 28Data Collection 26Magnetic Resonance Spectroscopy 25Nivolumab 20Watchful Waiting 20Immune Checkpoint Inhibitors 18Immunotherapy 17Magnetic Resonance Imaging 17Therapeutics 17Standard of Care 16trastuzumab deruxtecan 14Liquid Biopsy 13Tomography, X-Ray Computed 13palbociclib 13Hematologic Tests 12Restraint, Physical 12Focus Groups 11Genetic Testing 11Bevacizumab 10Positron Emission Tomography Computed Tomography 10darolutamide 10enzalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Observational × Trastuzumab × 1 year × Clear all
NCT06663787 2026-05-13

HER2 CR

Nagoya City University

Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT03738553 2026-05-04

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

University of Washington

Terminated
13 enrolled
Breast

HER2-positive Breast Cancer

NCT04158258 2026-04-23

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Hoffmann-La Roche

Active not recruiting
2,907 enrolled
Breast

Breast Neoplasms

NCT07416409 2026-02-18

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

Deraya University

Completed
80 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT06961331 2026-01-09

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Pfizer

Completed
86 enrolled
Breast

Breast Neoplasms

NCT03199300 2025-12-11

InvestiCAT

University Medical Center Groningen

Active not recruiting
20 enrolled
Tumor-Agnostic

Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡